Legend Biotech, a global novel cell therapy spin-off of Hong Kong-listed biotech company GenScript Biotech, has filed for an initial public offering (IPO) on the Nasdaq Stock Exchange.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
